Thermo Fisher Scientific Joins Cancer Moonshot Effort
October 17 2016 - 3:30PM
Business Wire
Commitment to Vice President Biden’s initiative
is part of larger precision medicine effort
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in
serving science, has joined the Cancer Moonshot, an initiative led
by Vice President Joe Biden aimed at making more therapies
available to more patients while also improving cancer detection at
early stages and, ultimately, preventing the disease. Initially,
Thermo Fisher will join a liquid biopsy-based precision oncology
pilot, called the Blood Profiling Atlas designed to make it easier
for oncologists to access databases of liquid biopsy information
when diagnosing patients.
“The Cancer Moonshot is an ambitious, all-hands initiative that
requires the best minds and best technologies working
collaboratively,” said Marc N. Casper, president and chief
executive officer of Thermo Fisher Scientific. “As part of our
broader focus on precision medicine, which includes investments to
accelerate the development of more effective cancer screening,
detection, monitoring and treatment, we’re honored to contribute
our data and expertise to this important initiative.”
Thermo Fisher is already an active collaborator globally in the
war on cancer, working with governments and private sector partners
alike to support advancements in precision medicine. Active
projects include the National Cancer Institute’s Molecular Analysis
for Therapy Choice (NCI-MATCH) clinical trial in the U.S. The
company is also supporting groundbreaking research by the
Karolinska Institute in Sweden to demonstrate the potential of
integrating both protein biomarkers and genetic markers in a single
test for prostate cancer.
Consistent with the Cancer Moonshot mission, Thermo Fisher is
focused on helping to make precision medicine technologies more
mainstream so that new diagnostics and therapies have clinical
application and utility. Current research under way includes
developing cell-free DNA (ct-DNA) tumor detection tests, providing
more effective ways to monitor responses to immunotherapy and
advancing liquid biopsy techniques.
“Thermo Fisher’s unique breadth of precision medicine solutions
enables us to play an important role in initiatives such as the
Cancer Moonshot,” said Alan Sachs, chief scientific officer for
Thermo Fisher. “From mass spectrometry for protein research to
next-generation targeted gene sequencing, we can offer a wealth of
technologies, insight and data to make an immediate contribution to
the work that other collaborators are already doing.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in
serving science, with revenues of $17 billion and more than 50,000
employees in 50 countries. Our mission is to enable our customers
to make the world healthier, cleaner and safer. We help our
customers accelerate life sciences research, solve complex
analytical challenges, improve patient diagnostics and increase
laboratory productivity. Through our premier brands – Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and
Unity Lab Services – we offer an unmatched combination of
innovative technologies, purchasing convenience and comprehensive
support. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017006376/en/
Thermo Fisher Scientific Inc.Media Contact Information:Ron
O’Brien, 781-622-1242ron.obrien@thermofisher.comWebsite:
www.thermofisher.comorInvestor Contact Information:Ken Apicerno,
781-622-1294ken.apicerno@thermofisher.comorGovernment Contact
Information:Tim Fenton, 202-257-4277tim.fenton@thermofisher.com
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Oct 2023 to Oct 2024